Allogene Therapeutics, Inc.

NASDAQ:ALLO

Biotechnology

Healthcare
$0.70 +1.02%

+$0.02 today

Market cap
$241.11M
Beta
0.46
P/E (TTM)
-2.7
EPS (TTM)
-$0.72
52W Low $0.98High $4.46

Volume 10.55M

Average 10.19M

ALLO Common Stock

The par or stated value of issued common shares, plus paid-in capital where reported together.

Allogene Therapeutics, Inc.NASDAQ: ALLO

Common Stock · Q1 FY2026 · quarter ended Mar 2026

Common stock rises 11.9% from a year ago

Common stock stood at $245K at the end of Q1 FY2026, up 11.9% from a year earlier and up 7.0% from the prior quarter. Over 3 fiscal years it compounded at +16.7% a year.

Context

  • Common stock amounted to 0.1% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Common stock increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether common stock keeps rising in the next quarterly balance sheet after a +11.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$245K+7.0% QoQ
Last fiscal yearDec 2025
$229K+8.0% YoY
Year agoMar 2025
$219K+11.9% since
Common Stock past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+11.9%——
1 year+8.0%——
3-year CAGR+16.7%——
5-year CAGR——
10-year CAGR——

Common Stock history

USD · from the balance sheet

Latest · FY2025
229K USD
Year-over-year change
+8.0%
4-year CAGR
+12.7%

Common Stock vs competitors

How ALLO compares with its peers on the latest reported figures

  • ALLO's Mar 2026 common stock of $245K is the 2nd highest of the 9 companies compared; the peer median is $11K.
  • Its year-over-year change of +11.9% is the 3rd highest of 9, against a peer median of +0.6%.
  • Common stock amounts to 0.1% of total assets for ALLO, versus a peer median of 0.0%.
ALLO Competitors Peer median
Common Stock for ALLO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CLLSCellectis S.A.Mar 2026$5.92M +0.3%+25.9%2.0%
ALLOAllogene Therapeutics, Inc.Mar 2026$245K +11.9%+16.7%0.1%
FATEFate Therapeutics, Inc.Mar 2026$116K +0.9%+5.8%0.0%
IPSCCentury Therapeutics, Inc.Mar 2026$18K +100.0%+14.5%0.0%
AUTLAutolus Therapeutics plcMar 2026$12K +0.0%+14.5%0.0%
CRBUCaribou Biosciences, Inc.Mar 2026$10K +11.1%+14.5%0.0%
CELUCelularity Inc.Dec 2025$3K +50.0%-41.5%0.0%
DTILPrecision BioSciences, Inc.Mar 2026$1K +0.0%+0.0%0.0%
ATRAAtara Biotherapeutics, Inc.Mar 2026$1K +0.0%-53.6%0.0%
Peer median (excluding ALLO) $11K+0.6%+10.2%0.0%

Competitors are the stored peer set for ALLO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents173.31M61.9M83.16M75.22M51.69M
Short-term Investments283.99M455.42M365.54M217.26M198.52M
Net Receivables001.7M1.9M1.5M
Inventory00000
Other Current Assets011.5M09.01M6.04M
Total Current Assets471.32M528.82M459.12M303.39M257.75M
Property, Plant & Equipment (Net)181.02M196.43M163.18M131.26M112.73M
Goodwill00000
Intangible Assets00000
Long-term Investments382.38M76.47M3.65M80.67M8.04M
Tax Assets00000
Other Non-current Assets16.11M19.86M16.9M33.39M37.39M
Total Non-current Assets579.51M292.76M183.72M245.32M158.16M
Total Assets1.05B821.58M642.84M548.71M415.91M
Account Payables10.26M13.89M5.9M5.39M4.27M
Short-term Debt00000
Tax Payables00000
Deferred Revenue156K95K86K00
Other Current Liabilities16.13M17.94M11.66M12.15M10.24M
Total Current Liabilities47.91M53.73M37.08M35.52M32.51M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities7.79M5.85M5.18M7.76M15.8M
Total Non-current Liabilities77.72M100.97M93.53M91.01M90.85M
Total Liabilities125.63M154.7M130.6M126.53M123.36M
Common Stock142K144K169K212K229K
Retained Earnings(894.55M)(1.23B)(1.56B)(1.82B)(2.01B)
Accumulated OCI(2.57M)(9.93M)(955K)(89K)269K
Other Stockholders Equity00000
Minority Interest00000
Total Equity925.2M666.88M512.23M422.18M292.54M
Total Debt73.13M101.12M95.12M90.76M83.25M
Net Debt(100.19M)39.22M11.97M15.54M31.57M

Allogene Therapeutics, Inc.

NASDAQ:ALLO

Intrinsic Alpha fair value

Locked

Current Price

$0.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.